RGNX
What one share of REGENXBIO holds
Biological Products, (No Diagnostic Substances)
We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease.
REGENXBIO’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.34 |
|---|---|
| Profit | −$3.76 |
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$4.79 |
| Cash and investments | $1.95 |
| Book value | $1.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.17 | −$2.38 | $0.31 | −$2.15 | — | $6.11 |
| 2017 | $0.35 | −$2.45 | $0.24 | −$2.18 | — | $5.85 |
| 2018 | $5.96 | $2.73 | $0.36 | $2.49 | — | $14.09 |
| 2019 | $0.96 | −$2.58 | $0.32 | −$3.25 | — | $12.17 |
| 2020 | $4.15 | −$2.98 | $0.72 | −$2.17 | — | $10.08 |
| 2021 | $10.71 | $2.91 | $1.92 | $3.07 | — | $17.84 |
| 2022 | $2.61 | −$6.50 | $0.71 | −$5.52 | — | $11.92 |
| 2023 | $2.06 | −$6.02 | $0.23 | −$5.22 | — | $7.08 |
| 2024 | $1.68 | −$4.59 | $0.05 | −$3.55 | — | $5.24 |
| 2025 | $3.30 | −$3.76 | $0.05 | −$2.45 | — | $2.02 |